Despite the mishap on the Bavi NSCLC Phase II trial, the important result was the FDA Phase III approval. All the posting on the Fargo issues that skips over this critical point is somewhere between irrelevant and misleading in my view. The only Fargo matter that interests me is the money Peregrine might get from CSM.
Let's look forward, not back. If there were any lessons to be learned from the matter, I think we can be sure that Peregrine management learned them all too well.
Market Data 
Markets 
AI
